VALRELEASE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VALRELEASE (VALRELEASE).
Increases GABAergic transmission by inhibiting GABA transaminase and blocking voltage-gated sodium channels.
| Metabolism | Hepatic via glucuronidation and beta-oxidation; CYP450 not significantly involved. |
| Excretion | Renal: 70-80% as metabolites (valproic acid glucuronide, 3-oxo-valproate, 2-en-valproate) and <3% unchanged. Hepatic: 15-20% via bile into feces. Other: 1-3% exhaled as CO2. |
| Half-life | Terminal elimination half-life is 6-16 hours (mean 10.6 h) in adults; shorter at 4-12 h in children due to enhanced clearance; prolonged to 12-18 h in hepatic impairment or elderly. Clinical context: Once-daily dosing requires extended-release formulation (Valrelease) to maintain trough levels. |
| Protein binding | 88-92% bound, primarily to albumin. Binding is concentration-dependent and saturable at high levels (>100 mcg/mL), leading to increased free fraction. |
| Volume of Distribution | 0.13-0.23 L/kg (mean 0.16 L/kg) in adults; higher in neonates (0.3-0.4 L/kg). Clinical meaning: Low Vd reflects limited extravascular distribution, with higher concentrations in brain due to active transport. |
| Bioavailability | Oral (extended-release): Approximately 100% relative to immediate-release valproic acid when adjusting for dose; slightly lower due to incomplete absorption (about 90% absorbed). |
| Onset of Action | Oral (extended-release): Steady-state in 3-4 days; clinical effect (seizure control) may be seen within 1-2 weeks with dose titration. |
| Duration of Action | Dosing interval: 24 hours due to extended-release design; clinical effect duration depends on therapeutic serum levels (50-100 mcg/mL). Continuous seizure protection over 24 h with consistent trough concentrations. |
500 mg orally twice daily, extended-release formulation. Maximum dose: 2000 mg/day.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | GFR 30-49 mL/min: 25% dose reduction; GFR 15-29 mL/min: 50% dose reduction; GFR <15 mL/min: avoid use. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated. |
| Pediatric use | For weight ≥25 kg: 20 mg/kg/day divided twice daily, maximum 1000 mg/day. Adjust based on therapeutic response. |
| Geriatric use | Initiate at 250 mg twice daily; increase slowly due to decreased renal function and increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VALRELEASE (VALRELEASE).
| Breastfeeding | Valproate is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.05-0.1, resulting in infant serum levels 1-10% of maternal levels. The American Academy of Pediatrics considers it compatible with breastfeeding; however, monitor infant for thrombocytopenia, hepatic dysfunction, and sedation. |
| Teratogenic Risk | First trimester: Valproate is associated with a 3-5% risk of neural tube defects (e.g., spina bifida), as well as increased risks of orofacial clefts, cardiovascular malformations, and hypospadias. Second and third trimesters: Exposure may lead to neurodevelopmental deficits, including lower IQ and autism spectrum disorders. Fetal valproate syndrome (craniofacial abnormalities, limb defects) is documented. |
■ FDA Black Box Warning
WARNING: TERATOGENICITY - VALRELEASE can cause fetal harm. Women of childbearing potential must use effective contraception.
| Serious Effects |
["Hypersensitivity to valproate","Hepatic disease or significant dysfunction","Urea cycle disorders","Known mitochondrial disorders (e.g., POLG mutations)"]
| Precautions | ["Hepatotoxicity","Pancreatitis","Hyperammonemia","Teratogenicity","Somnolence","Thrombocytopenia"] |
Loading safety data…
| Fetal Monitoring | Pre-pregnancy and throughout: Ensure folate supplementation (5 mg/day) to reduce neural tube defect risk. First trimester: High-resolution ultrasound and fetal echocardiography at 18-20 weeks gestation. Third trimester: Monitor maternal valproate trough levels (target seizure control with lowest effective dose), liver function tests, complete blood count, and coagulation profile. Neonatal: Observe for withdrawal symptoms (irritability, feeding difficulties) and coagulation abnormalities (vitamin K prophylaxis recommended). |
| Fertility Effects | Valproate may cause menstrual irregularities, anovulation, and polycystic ovary syndrome (PCOS)-like symptoms, potentially impairing fertility. These effects are reversible upon treatment discontinuation. Male fertility may be affected by reduced sperm motility and count, though data are limited. |